Your browser doesn't support javascript.
Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective.
Skevaki, Chrysanthi; Chinthrajah, R Sharon; Fomina, Daria; Rohde, Gernot; Cao, Shu; He, Ziyuan; Serdotetskova, Sofia; Seidemann, Christian; Grünewaldt, Achim; Vengadeswaran, Abisha; Xie, Min; Karsonova, Antonina; Karaulov, Alexander; Nadeau, Kari C; Chung, Ho-Ryun; Renz, Harald.
  • Skevaki C; Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany; Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, Marburg, Germany. Electronic address: Chrysanthi.Skevaki@uk-gm.de.
  • Chinthrajah RS; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
  • Fomina D; Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia; Moscow City Research and Practical Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russia.
  • Rohde G; Department of Respiratory Medicine, University Hospital Frankfurt, Frankfurt, Germany; CAPNETZ Foundation, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), the German Center for Lung Research, Hannover, Germany.
  • Cao S; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
  • He Z; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
  • Serdotetskova S; Moscow City Research and Practical Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russia.
  • Seidemann C; Department of Data Integration Center, MIRACUM, Philipps University Marburg, Marburg, Germany.
  • Grünewaldt A; Department of Respiratory Medicine, University Hospital Frankfurt, Frankfurt, Germany.
  • Vengadeswaran A; Institute for Medical Informatics, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt, Germany.
  • Xie M; Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Karsonova A; Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia.
  • Karaulov A; Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia.
  • Nadeau KC; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
  • Chung HR; Institute for Medical Bioinformatics and Biostatistics, Philipps University Marburg, Marburg, Germany.
  • Renz H; Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany; Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, Marburg, Germany; Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov Un
J Allergy Clin Immunol ; 2022 Nov 03.
Article in English | MEDLINE | ID: covidwho-2235736
ABSTRACT

BACKGROUND:

The global epidemiology of asthma among patients with coronavirus disease 2019 (COVID-19) presents striking geographic differences, defining prevalence zones of high and low co-occurrence of asthma and COVID-19.

OBJECTIVE:

We aimed to compare asthma prevalence among hospitalized patients with COVID-19 in major global hubs across the world by applying common inclusion criteria and definitions.

METHODS:

We built a network of 6 academic hospitals in Stanford (Stanford University)/the United States; Frankfurt (Goethe University), Giessen (Justus Liebig University), and Marburg (Philipps University)/Germany; and Moscow (Clinical Hospital 52 in collaboration with Sechenov University)/Russia. We collected clinical and laboratory data for patients hospitalized due to COVID-19.

RESULTS:

Asthmatic individuals were overrepresented among hospitalized patients with COVID-19 in Stanford and underrepresented in Moscow and Germany as compared with their prevalence among adults in the local community. Asthma prevalence was similar among patients hospitalized in an intensive care unit and patients hospitalized in other than an intensive care unit, which implied that the risk for development of severe COVID-19 was not higher among asthmatic patients. The numbers of males and comorbidities were higher among patients with COVID-19 in the Stanford cohort, and the most frequent comorbidities among these patients with asthma were other chronic inflammatory airway disorders such as chronic obstructive pulmonary disease.

CONCLUSION:

The observed disparity in COVID-19-associated risk among asthmatic patients across countries and continents is connected to the varying prevalence of underlying comorbidities, particularly chronic obstructive pulmonary disease.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article